The epoxyketone-based proteasome inhibitors carfilzomib and orally bioavailable oprozomib have anti-resorptive and bone-anabolic activity in addition to anti-myeloma effects
- PMID: 22763387
- PMCID: PMC3771507
- DOI: 10.1038/leu.2012.183
The epoxyketone-based proteasome inhibitors carfilzomib and orally bioavailable oprozomib have anti-resorptive and bone-anabolic activity in addition to anti-myeloma effects
Abstract
Proteasome inhibitors (PIs), namely bortezomib, have become a cornerstone therapy for multiple myeloma (MM), potently reducing tumor burden and inhibiting pathologic bone destruction. In clinical trials, carfilzomib, a next generation epoxyketone-based irreversible PI, has exhibited potent anti-myeloma efficacy and decreased side effects compared with bortezomib. Carfilzomib and its orally bioavailable analog oprozomib, effectively decreased MM cell viability following continual or transient treatment mimicking in vivo pharmacokinetics. Interactions between myeloma cells and the bone marrow (BM) microenvironment augment the number and activity of bone-resorbing osteoclasts (OCs) while inhibiting bone-forming osteoblasts (OBs), resulting in increased tumor growth and osteolytic lesions. At clinically relevant concentrations, carfilzomib and oprozomib directly inhibited OC formation and bone resorption in vitro, while enhancing osteogenic differentiation and matrix mineralization. Accordingly, carfilzomib and oprozomib increased trabecular bone volume, decreased bone resorption and enhanced bone formation in non-tumor bearing mice. Finally, in mouse models of disseminated MM, the epoxyketone-based PIs decreased murine 5TGM1 and human RPMI-8226 tumor burden and prevented bone loss. These data demonstrate that, in addition to anti-myeloma properties, carfilzomib and oprozomib effectively shift the bone microenvironment from a catabolic to an anabolic state and, similar to bortezomib, may decrease skeletal complications of MM.
Conflict of interest statement
CJK is an employee of Onyx Pharmaceuticals. All other authors declare no conflict of interest.
Figures







Similar articles
-
Pulse treatment with the proteasome inhibitor bortezomib inhibits osteoclast resorptive activity in clinically relevant conditions.Leuk Res. 2008 Nov;32(11):1661-8. doi: 10.1016/j.leukres.2008.02.019. Epub 2008 Apr 18. Leuk Res. 2008. PMID: 18394701
-
Biological aspects of altered bone remodeling in multiple myeloma and possibilities of pharmacological intervention.Dan Med Bull. 2011 May;58(5):B4277. Dan Med Bull. 2011. PMID: 21535989 Review.
-
A novel Bruton's tyrosine kinase inhibitor CC-292 in combination with the proteasome inhibitor carfilzomib impacts the bone microenvironment in a multiple myeloma model with resultant antimyeloma activity.Leukemia. 2014 Sep;28(9):1892-901. doi: 10.1038/leu.2014.69. Epub 2014 Feb 12. Leukemia. 2014. PMID: 24518207
-
Preclinical activity of the oral proteasome inhibitor MLN9708 in Myeloma bone disease.Clin Cancer Res. 2014 Mar 15;20(6):1542-54. doi: 10.1158/1078-0432.CCR-13-1657. Epub 2014 Jan 31. Clin Cancer Res. 2014. PMID: 24486586
-
Role of bone-anabolic agents in the treatment of breast cancer bone metastases.Breast Cancer Res. 2014;16(6):484. doi: 10.1186/s13058-014-0484-9. Breast Cancer Res. 2014. PMID: 25757219 Free PMC article. Review.
Cited by
-
Evaluating Acetate Metabolism for Imaging and Targeting in Multiple Myeloma.Clin Cancer Res. 2017 Jan 15;23(2):416-429. doi: 10.1158/1078-0432.CCR-15-2134. Epub 2016 Aug 2. Clin Cancer Res. 2017. PMID: 27486177 Free PMC article.
-
Carfilzomib with immunomodulatory drugs for the treatment of newly diagnosed multiple myeloma.Leukemia. 2019 Sep;33(9):2127-2143. doi: 10.1038/s41375-019-0517-6. Epub 2019 Jul 24. Leukemia. 2019. PMID: 31341235 Free PMC article. Review.
-
3D Printing of Tricalcium Phosphate/Poly Lactic-co-glycolic Acid Scaffolds Loaded with Carfilzomib for Treating Critical-sized Rabbit Radial Bone Defects.Int J Bioprint. 2021 Sep 14;7(4):405. doi: 10.18063/ijb.v7i4.405. eCollection 2021. Int J Bioprint. 2021. PMID: 34805594 Free PMC article.
-
Bone Marrow Mesenchymal Stromal Cells in Multiple Myeloma: Their Role as Active Contributors to Myeloma Progression.Cancers (Basel). 2021 May 22;13(11):2542. doi: 10.3390/cancers13112542. Cancers (Basel). 2021. PMID: 34067236 Free PMC article. Review.
-
Animal Models of Multiple Myeloma Bone Disease.Front Genet. 2021 Jun 7;12:640954. doi: 10.3389/fgene.2021.640954. eCollection 2021. Front Genet. 2021. PMID: 34163520 Free PMC article. Review.
References
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous